Shots:

• The P-III (ADVANCE) trial evaluating Vyvgart in a ratio (2:1) in 131 patients with chronic & persistent ITP across the EU, North America & Japan for 24wks. The results from the (ADVANCE-SC) trial are expected in Q1’23
• The trial met its 1EPs i.e., patients achieved a sustained platelet response b/w 19 & 24wks. The 2EPs showed a significant benefit in the chronic ITP population & sustained platelet response in the overall population
• Additionally, 51.2% vs 20% were classified as IWG responders & 27.9% vs 4.4% as complete responders & showed platelet count improvement with significant separation from PBO @1wk. & maintained through 20wks., safety and tolerability were consistent with prior trials

Ref: Globenewswire | Image: Zai Lab